Tadashi Shimamura

This inventor holds 17 USPTO granted patents and 6 published patent applications, plus 4 CIPO patents and 7 EPO patents. Top assignees: Taiho Pharmaceutical Company Limited, Msd K.k., Merck Sharp + Dohme Corp.. Active years: 2010-2025.

USPTO Granted Patents = 17 (Patent Applications = 6)

% Patents Active = 88.2

CIPO Patents = 4 (Patent Applications = 4)

EPO Patents = 7 (Patent Applications = 10)

Average Co-Inventor Count = 4.0

ph-index = 2

Forward Citations = 13(Granted Patents)

Location History:

Tsukuba, JP (2010 - 2022)
Ibaraki, JP (2024)

Company Filing History:

13 out of 320

Taiho Pharmaceutical Company Limited

Merck Sharp + Dohme Corp.

patents

4. 2 out of 846

Otsuka Pharmaceutical Company, Limited

patents

5. 1 out of 237

Banyu Pharmaceutical Co. Ltd

patents

where one patent can have more than one assignee

Years Active: 2010-2025

Loading Chart...

17 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12458640 - Pyrazolo[3,4-b]pyrazine SHP2 phosphatase inhibitors (2025-11-04),

2. 12215109 - Crystal of pyrazolo[3,4-d]pyrimidine (2025-02-04),

3. 12037345 - Heterobicyclic compounds for inhibiting the activity of SHP2 (2024-07-16),

4. 11236096 - Fused pyrimidine compound or salt thereof (2022-02-01),

5. 11046696 - Fused pyrimidine compound or salt thereof (2021-06-29),

6. 11014930 - Fused pyrimidine compound or salt thereof (2021-05-25),

7. 10807986 - Fused pyrimidine compound or salt thereof (2020-10-20),

8. 10787457 - Fused pyrimidine compound or salt thereof (2020-09-29),

9. 10233189 - Fused pyrimidine compound or salt thereof (2019-03-19),

10. 10155768 - Fused pyrimidine compound or salt thereof (2018-12-18),

11. 9845329 - Method for producing a substituted 6,7,8,9-tetrahydropyrimido[5,4-b]indolizine, substituted 7,8,9,10-tetrahydro-6H-pyrimido[5',4′:4,5]pyrrolo[1,2-a]azepine and substituted 6,7,8,9,10,11-hexahydropyrimido[5′,4′:4,5]pyrrolo[1,2-a]azocine (2017-12-19),

12. 9758526 - Quinoline-substituted compound (2017-09-12),

13. 9650386 - Quinoline-substituted compound (2017-05-16),

14. 8362052 - Isoindolin-1-one derivative (2013-01-29),

15. 8138197 - Spirochromanon derivatives (2012-03-20),

Title: **Tadashi Shimamura: A Pioneer in Pyrazolo and Heterobicyclic Compounds**

Introduction

Tadashi Shimamura, an esteemed inventor located in Tsukuba, Japan, has made significant contributions to the field of chemical inventions. With a portfolio of 16 patents, his work predominantly focuses on innovative compounds that enhance various applications, particularly in pharmaceutical development.

Latest Patents

One of Shimamura's latest innovations is the patent for a crystal of pyrazolo[3,4-d]pyrimidine. This invention aims to provide a crystal form of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-N-(4-(2-(dimethylamino)-2-oxoethyl)-2,3-dimethylphenyl)-1H-pyrazolo[3,4-d]pyrimidine-3-carboxamide, noted for its excellent stability and suitability for manufacturing and formulation purposes. The patent outlines a crystal possessing an X-ray powder diffraction spectrum with distinctive peaks at specific diffraction angles, which further validates its unique properties.

Additionally, Shimamura has been involved in the development of heterobicyclic compounds for inhibiting the activity of SHP2, which are poised to play a key role in therapeutic applications targeting various diseases.

Career Highlights

Throughout his career, Shimamura has been associated with well-known organizations such as Taiho Pharmaceutical Company Limited and MSD K.K. His experience in these prominent firms has allowed him to refine his expertise in drug development and innovation.

Collaborations

Tadashi Shimamura has collaborated with esteemed colleagues like Isao Miyazaki and Masanori Kato. Their joint efforts have significantly contributed to advancing the knowledge and capabilities within their field, further enhancing innovation in pharmaceutical sciences.

Conclusion

Tadashi Shimamura’s contributions to the realm of chemical inventions are invaluable. With his extensive patent portfolio and collaborations with industry professionals, he continues to impact the pharmaceutical landscape positively. His focus on stability and formulation in his recent inventions reflects a commitment to advancing science and technology for better therapeutic solutions.